<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02217657</url>
  </required_header>
  <id_info>
    <org_study_id>MucM001-13</org_study_id>
    <nct_id>NCT02217657</nct_id>
  </id_info>
  <brief_title>SmartTouch Catheter for Left Anterior Line - SmarT Line Study</brief_title>
  <official_title>&quot;Bidirectional Conduction Block of Left Atrial Anterior Line in Patients With Left Atrial Ablation - Reduction of RF Applications Using the Thermocool SmartTouch Contact Force Sensing Catheter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinikum der Universitaet Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Klinikum der Universitaet Muenchen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, randomized study will investigate, if information of the catheter force
      during ablation of a left anterior line does reduce total RF application time by prevention
      of ineffective lesions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Catheter ablation has emerged as a realistic therapeutic option for symptomatic atrial
      fibrillation (AF).

      The three main techniques described for ablation of persistent AF include pulmonary vein (PV)
      isolation, ablation based on electrogram analysis, and left atrial (LA) linear lesions.

      The ideal endpoint of linear lesions should be complete electrical block; however, this is
      technically challenging, time consuming, and potentially hazardous. The ST catheter combined
      with 3D mapping and navigation software, gives physicians a real-time, objective measure of
      tip-to-tissue contact force during the catheter ablation procedure and will allow physicians
      to more safely and effectively treat atrial fibrillation.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of total RF application until bidirectional conduction block across the anterior line is achieved (including a waiting period of 30 minutes)</measure>
    <time_frame>30 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achievement of primary endpoint (bidirectional conduction block at an anterior line)</measure>
    <time_frame>6 months</time_frame>
    <description>Achievement of primary endpoint (bidirectional conduction block at an anterior line). Procedure Duration. Reduction of local potential amplitude during SR or atrial fibrillation after 60 seconds of ablation. Freedom of any atrial tachyarrhythmia at 7 day holter 3 and 6 months after a single ablation procedure. Freedom of any symptoms of atrial arrhythmias 6 months after ablation (except during blanking period of 6 weeks). Confirmation of gap-freeness in MRI (3-6 months after ablation). Quality of Life (atrial fibrillation symptom checklist und major depression index) pre, 3 and 6 months after Ablation. Safety (bleeding, pericardial effusion, thrombembolic events).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>operator informed to contact force</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Thermocool Smart Touch Catheter, operator informed to contact force (Biosense Webster)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>operator blinded to contact force</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thermocool Smart Touch catheter, operator blinded to contact force information (Biosense Webster)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Thermocool Smart Touch Catheter</intervention_name>
    <description>Physician informed to contact force</description>
    <arm_group_label>operator informed to contact force</arm_group_label>
    <arm_group_label>operator blinded to contact force</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with symptomatic atrial fibrillation and additional substrate modification or
             perimitral flutter

          -  Patients with persistent atrial fibrillation

          -  Patients with perimitral flutter

          -  Patients with recurrence after a circumferential PV isolation procedure

          -  Patients with paroxysmal atrial fibrillation and AF episodes lasting &gt; 7 days

          -  Patients (&gt;18 und &lt;80 Jahre)

        Exclusion Criteria:

          -  moderate to severe valvular heart disease,

          -  congenital heart disease

          -  reduced left ventricular function (ejection fraction &lt;35%)

          -  any reversible cause for atrial fibrillation (e.g. hyperthyroidism)

          -  intracardiac thrombi documented by transesophageal echocardiography

          -  myocardial infarction within 3 months, cardiac surgery in the previous three months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heidi Estner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Munich University Clinic, Campus Großhadern</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heidi Estner, MD</last_name>
    <phone>+49 89 4400</phone>
    <phone_ext>76036</phone_ext>
    <email>heidi.estner@med.uni-muenchen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Reza Wakili, MD</last_name>
    <phone>+49 89 4400</phone>
    <phone_ext>76036</phone_ext>
    <email>reza.wakili@med.uni-muenchen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Munich University Clinic, Campus Großhadern</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Estner, MD</last_name>
      <phone>+49-89-4400</phone>
      <phone_ext>73036</phone_ext>
      <email>heidi.estner@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Reza Wakili, MD</last_name>
      <phone>+49-89-4400</phone>
      <phone_ext>73036</phone_ext>
      <email>reza.wakili@med.uni-muenchen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Heidi Estner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2014</study_first_submitted>
  <study_first_submitted_qc>August 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2014</study_first_posted>
  <last_update_submitted>May 30, 2016</last_update_submitted>
  <last_update_submitted_qc>May 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Klinikum der Universitaet Muenchen</investigator_affiliation>
    <investigator_full_name>Heidi Estner</investigator_full_name>
    <investigator_title>Director Interventional Electrophysiology</investigator_title>
  </responsible_party>
  <keyword>Smart-Touch</keyword>
  <keyword>Contact force</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

